Ameriprise
TEVA icon

Ameriprise’s Teva Pharmaceuticals TEVA Stock Holding History

Ameriprise’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-37,100
Closed -$2.19M – 3937
2015
Q2 		$2.19M Buy
+37,100
New +$2.29M ﹤0.01% 2697

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise's TEVA Position: Q1 2026 in Review

Ameriprise reduced its Teva Pharmaceuticals (TEVA) stake by 0.15% in Q1 2026, selling an estimated $5.21K and leaving 111,491 shares worth $3.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2692.

Ameriprise first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $163M in Q4 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Ameriprise held 111,491 shares of Teva Pharmaceuticals worth $3.36M as of Q1 2026.
  • Ameriprise sold 162 Teva Pharmaceuticals shares in Q1 2026, an estimated $5.21K.
  • Teva Pharmaceuticals made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2692 holding.
  • Ameriprise first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Ameriprise's Teva Pharmaceuticals position peaked at $163M in Q4 2015.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.